Mitchell & Pahl Private Wealth LLC Lowers Stake in Astrazeneca Plc $AZN

Mitchell & Pahl Private Wealth LLC cut its stake in Astrazeneca Plc (NYSE:AZN) by 50.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,142 shares of the company’s stock after selling 7,146 shares during the period. Mitchell & Pahl Private Wealth LLC’s holdings in Astrazeneca were worth $1,409,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in AZN. Arrowstreet Capital Limited Partnership boosted its position in Astrazeneca by 552.9% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 5,547,597 shares of the company’s stock valued at $973,603,000 after buying an additional 4,697,895 shares during the period. Pictet Asset Management Holding SA bought a new position in Astrazeneca in the 1st quarter worth about $675,263,000. Bank of Montreal Can increased its position in shares of Astrazeneca by 344.6% during the third quarter. Bank of Montreal Can now owns 3,478,114 shares of the company’s stock worth $266,841,000 after acquiring an additional 2,695,793 shares during the period. Lansforsakringar Fondforvaltning AB publ purchased a new position in shares of Astrazeneca during the first quarter worth approximately $473,782,000. Finally, ABN AMRO Bank N.V. raised its stake in shares of Astrazeneca by 32,441.5% during the first quarter. ABN AMRO Bank N.V. now owns 2,445,171 shares of the company’s stock valued at $482,158,000 after acquiring an additional 2,437,657 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

AZN has been the subject of a number of research reports. The Goldman Sachs Group reiterated a “buy” rating on shares of Astrazeneca in a report on Wednesday. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Astrazeneca in a research report on Tuesday. Barclays reiterated a “buy” rating on shares of Astrazeneca in a report on Monday, June 1st. Weiss Ratings downgraded Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, June 18th. Finally, Jefferies Financial Group restated a “buy” rating on shares of Astrazeneca in a research note on Friday, June 26th. Fourteen research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $205.33.

Astrazeneca Stock Performance

Shares of AZN opened at $194.96 on Friday. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. The firm has a market cap of $302.36 billion, a PE ratio of 29.27, a P/E/G ratio of 1.49 and a beta of 0.24. Astrazeneca Plc has a 12 month low of $137.23 and a 12 month high of $212.71. The stock has a fifty day moving average price of $183.91 and a 200-day moving average price of $187.76.

Astrazeneca (NYSE:AZN) last announced its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The firm had revenue of $15.29 billion for the quarter, compared to the consensus estimate of $14.93 billion. Equities research analysts predict that Astrazeneca Plc will post 10.28 earnings per share for the current fiscal year.

Key Stories Impacting Astrazeneca

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: AstraZeneca announced a strategic collaboration with Abbisko Therapeutics to advance a Phase I/II clinical trial of lumipodlin (ABSK043) combined with Tagrisso for non-small cell lung cancer, adding another pipeline development opportunity. Article Title
• Positive Sentiment: AZN’s cancer drug Enhertu won another EU approval for HER2-positive solid tumors, extending its commercial footprint and reinforcing investor confidence in the company’s oncology franchise. Article Title
• Positive Sentiment: Goldman Sachs and Bank of America both reaffirmed “buy” ratings on AstraZeneca, while Erste Group raised its FY2026 EPS estimate, signaling continued analyst confidence in earnings power. Article Title
• Positive Sentiment: Separate style-score coverage from Zacks highlighted AZN as both a strong value stock and a strong momentum stock, which may have supported buying interest. Article Title
• Neutral Sentiment: MarketBeat noted that AstraZeneca’s shares have recently traded below some valuation-based fair value estimates, suggesting the stock still screens as expensive despite the recent rally.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.